Please provide your email address to receive an email when new articles are posted on . A single-arm, single-blind, phase 2a study of the neuromodulating drug RL-007, initiated by biopharmaceutical ...

REVISED WITH EXTRA COMMENTS 3/16/21 — Results from a phase 2 placebo-controlled trial of the investigational antiamyloid drug donanemab (Eli Lilly and Company) show that the novel agent met the ...

Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial of RL-007 These results support the progression of RL-007 to a double-blind, ...

The Alzheimer’s field begins 2021 with a glimmer of good news: Donanemab, a monoclonal antibody that recognizes a pyroglutamated form of Aβ, slowed cognitive decline in people with early AD. That was ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Benzoate treatment appeared to improve cognitive ...

A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three ...

LOS ANGELES, Dec. 8, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...

NEW YORK, April 6, 2021 /PRNewswire/ — Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment with initial ...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...

Cognitive health is a growing concern among adults 65 and older, with conditions affecting memory and mental performance ranking among the Top 10 chronic issues, according to the National Council on ...

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, ...